Immunology and Biotherapies
12.2K views | +8 today
Follow
 
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert C FAURE's insight:

We choose Scoop.it as the best curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Topical Imiquimod for the Treatment of Childhood Cutaneous Langerhans Cell Histiocytosis

Topical Imiquimod for the Treatment of Childhood Cutaneous Langerhans Cell Histiocytosis | Immunology and Biotherapies | Scoop.it
Although topical steroids are considered first-line treatment for cutaneous Langerhans cell histiocytosis (LCH), the appropriate therapy for refractory cases remains controversial.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

JHL Biotech opens new biosimilar manufacturing facility in China

JHL Biotech opens new biosimilar manufacturing facility in China | Immunology and Biotherapies | Scoop.it
JHL Biotech (JHL) opened the world’s first KUBio™ biopharmaceutical manufacturing facility with single-use bioprocessing technology at a ribbon-cutting ceremony in Wuhan, China.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Unmasking targets of antitumor immunity via high-throughput antigen profiling

Unmasking targets of antitumor immunity via high-throughput antigen profiling | Immunology and Biotherapies | Scoop.it
Publication date: December 2016 Source:Current Opinion in Biotechnology, Volume 42 Author(s): Sebastiano Battaglia, Jason B Muhitch More than three decades of evidence has established that antitumor immune responses, initially shown with...
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Concise Review: Cellular Therapies: The Potential to Regenerate and Restore Tolerance in Immune-Mediated Intestinal Diseases

Concise Review: Cellular Therapies: The Potential to Regenerate and Restore Tolerance in Immune-Mediated Intestinal Diseases | Immunology and Biotherapies | Scoop.it
Chronic inflammatory enteropathies, including celiac disease, Crohn's disease, and ulcerative colitis, are lifelong disabling conditions whose cure is still an unmet need, despite the great strides made in understanding their complex pathogenesis.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Understanding Jimmy Carter’s Surprise Cancer Turnaround: A Conversation with Jedd Wolchok

Understanding Jimmy Carter’s Surprise Cancer Turnaround: A Conversation with Jedd Wolchok | Immunology and Biotherapies | Scoop.it
Former President Carter’s recent announcement that he is “cancer free” has generated a lot of media attention. Here, we tackle some of the science behind the story.
Via Krishan Maggon
Gilbert C FAURE's insight:
for laypeople and master students
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Cell-Surface MMP-9 Protein Is a Novel Functional Marker to Identify and Separate Proangiogenic Cells from Early Endothelial Progenitor Cells Derived from CD133+ Cells

Cell-Surface MMP-9 Protein Is a Novel Functional Marker to Identify and Separate Proangiogenic Cells from Early Endothelial Progenitor Cells Derived from CD133+ Cells | Immunology and Biotherapies | Scoop.it
To develop cell therapies for ischemic diseases, endothelial progenitor cells (EPCs) have been expected to play a pivotal role in vascular regeneration. It is desirable to use a molecular marker that is related to the function of the cells.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Universal CAR-T given to Second baby with aggressive Leukemia

Universal CAR-T given to Second baby with aggressive Leukemia | Immunology and Biotherapies | Scoop.it
Once again, the French biotech Cellectis has hit headlines after having treated a second infant suffering from an aggressive form of Leukemia with their UCART19 therapy.
Gilbert C FAURE's insight:
avec une image didactique
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Achieving Best Product Purity and Recovery | GEN Magazine Articles | GEN

Achieving Best Product Purity and Recovery | GEN Magazine Articles | GEN | Immunology and Biotherapies | Scoop.it
Monoclonal antibody production is bedeviled by the formation of aggregates. According to Bio-Rad, aggregates can be removed (and yields sustained) by means of mixed-mode chromatography.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

First and only antibody for Multiple Myeloma approved in EU

First and only antibody for Multiple Myeloma approved in EU | Immunology and Biotherapies | Scoop.it
The European Biotech News Website
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

B Cells in the Spleen Manipulated to Treat Sepsis

B Cells in the Spleen Manipulated to Treat Sepsis | Immunology and Biotherapies | Scoop.it
B cells, which are mostly known for antibody production in the face of invading pathogens, provide another function in the form of marginal zone B cells in
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Stem cell organization to scientists: Enough with the hype!

Stem cell organization to scientists: Enough with the hype! | Immunology and Biotherapies | Scoop.it
Giving a misleading impression of the state of research is not a good thing.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies.

Related Articles
Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies.
Toxicol Pathol.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

FDA approves First ever antibody to target Cancer PD-L1

FDA approves First ever antibody to target Cancer PD-L1 | Immunology and Biotherapies | Scoop.it
The European Biotech News Website
Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

CAR models: next-generation CAR modifications for enhanced T-cell function

CAR models: next-generation CAR modifications for enhanced T-cell function | Immunology and Biotherapies | Scoop.it
MTO is an international, online-only, open-access journal focusing on the development and clinical testing of molecular therapies targeting cancer
more...
Krishan Maggon 's curator insight, May 19, 3:28 PM
Molecular Therapy — Oncolytics 3, Article number: 16014 (2016) ​doi:10.1038/mto.2016.14

Daniel Abate-Daga & Marco L Davila
Scooped by Gilbert C FAURE
Scoop.it!

Rapid and improved characterization of therapeutic antibodies and antibody related products using IdeS digestion and subunit analysis

Rapid and improved characterization of therapeutic antibodies and antibody related products using IdeS digestion and subunit analysis | Immunology and Biotherapies | Scoop.it
Analyst, 2016, Advance Article DOI: 10.1039/C6AN00071A, MinireviewJonathan Sjogren, Fredrik Olsson, Alain Beck Antibody subunits LC, Fd and Fc/2, generated by IdeS digestion has been applied in analytical methodologies to characterize antibody...
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

CAR T Cell Therapy: A Game Changer in Cancer Treatment

CAR T Cell Therapy: A Game Changer in Cancer Treatment | Immunology and Biotherapies | Scoop.it
The development of novel targeted therapies with acceptable safety profiles is critical to successful cancer outcomes with better survival rates. Immunotherapy offers promising opportunities with the potential to induce sustained remissions in patients with refractory disease. Recent dramatic clinical responses in trials with gene modified T cells expressing chimeric antigen receptors (CARs) in B-cell malignancies have generated great enthusiasm. This therapy might pave the way for a potential paradigm shift in the way we treat refractory or relapsed cancers. CARs are genetically engineered receptors that combine the specific binding domains from a tumor targeting antibody with T cell signaling domains to allow specifically targeted antibody redirected T cell activation. Despite current successes in hematological cancers, we are only in the beginning of exploring the powerful potential of CAR redirected T cells in the control and elimination of resistant, metastatic, or recurrent nonhematological cancers. This review discusses the application of the CAR T cell therapy, its challenges, and strategies for successful clinical and commercial translation.
Via Krishan Maggon
Gilbert C FAURE's insight:
scFv suite
more...
Krishan Maggon 's curator insight, May 19, 11:13 AM
Journal of Immunology Research Volume 2016 (2016), Article ID 5474602, 10 pages 

Hilde Almåsbak,1 Tanja Aarvak,1 and Mohan C. Vemuri2 
1Cellular Medicine, Bioproduction, Thermo Fisher Scientific, 0309 Oslo, Norway 2Cell Biology, Thermo Fisher Scientific, Frederick, MD 21704, USA
Scooped by Gilbert C FAURE
Scoop.it!

From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway

RT @PiescheM: From monoclonal antibodies 2 small molecules: development of inhibitors targeting #PD1/PDL1 pathway https://t.co/P7Rl2dvHpm #…
Gilbert C FAURE's insight:
chinese review
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

JHL Biotech opens biosimilars manufacturing facility in China

JHL Biotech opens biosimilars manufacturing facility in China | Immunology and Biotherapies | Scoop.it
Biopharmaceutical company JHL Biotech has opened the world’s first KUBio™ biopharma manufacturing facility with single-use bioprocessing technology at a ribbon-cutting ceremony in Wuhan, China.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

The world’s most expensive medicine costs $1 million and has been used just once

The world’s most expensive medicine costs $1 million and has been used just once | Immunology and Biotherapies | Scoop.it
REUTERS/Lucy Nicholson
The most expensive drug in history is a money loser that’s not reaching patients. In fact, it’s only been paid for and used commercially once since being approved in 2012.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Clinical & Translational Immunology - Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway

Clinical & Translational Immunology - Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway | Immunology and Biotherapies | Scoop.it
Clinical & Translational Immunology focuses on the general functioning of the immune system in its broadest sense, with a particular emphasis on its cell biology. Areas that are covered include but are not limited to: Cellular immunology, Innate and adaptive immunity, Immune responses to pathogens,Tumour immunology,Immunopathology, Immunotherapy, Immunogenetics, Immunological studies in humans and model organisms (including mouse, rat, Drosophila etc)
Gilbert C FAURE's insight:
OPEN
more...
Suggested by Société Francaise d'Immunologie
Scoop.it!

Researchers discover potential treatment for sepsis and other responses to infection

Researchers at the Icahn School of Medicine at Mount Sinai say that tiny doses of a cancer drug may stop the raging, uncontrollable immune response to infection that leads to sepsis and kills up to 500,000 people a year in the U.S.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

An activation-induced IL-15 isoform is a natural antagonist for IL-15 function

An activation-induced IL-15 isoform is a natural antagonist for IL-15 function | Immunology and Biotherapies | Scoop.it
Interleukin 15 (IL-15) expression induces the secretion of inflammatory cytokines, inhibits the apoptosis of activated T cells and prolongs the survival of CD8+ memory T cells.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Regeneron says anti-NGF fasinumab works in pain - PMLiVE

Regeneron says anti-NGF fasinumab works in pain - PMLiVE | Immunology and Biotherapies | Scoop.it
Regeneron says #antiNGF fasinumab works in #pain | https://t.co/EysIARMoa5 (Via @PMLiVEcom)
more...
No comment yet.